Akebia Therapeutics Inc. buy BTIG Research
Start price
02.12.25
/
50%
€1.27
Target price
02.12.26
€4.31
Performance (%)
-6.28%
Price
16.04.26
€1.25
Summary
This prediction is currently active. With a performance of -6.28%, the BUY prediction by BTIG_Research is trending in the wrong direction. This prediction currently runs until 02.12.26. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | 4.504% | 4.504% |
| iShares Core DAX® | 3,59 % | 3,93 % |
| iShares Nasdaq 100 | 5,81 % | 5,52 % |
| iShares Nikkei 225® | 4,08 % | 8,46 % |
| iShares S&P 500 | 4,14 % | 4,04 % |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Stopped prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.18
07.04.26
07.04.26
€3.47
07.04.27
07.04.27
6.55%
16.04.26
16.04.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.08
25.02.26
25.02.26
€3.39
25.02.27
25.02.27
10.97%
16.04.26
16.04.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.93
29.10.25
29.10.25
€4.29
29.10.26
29.10.26
-38.07%
16.04.26
16.04.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
29.11.23
29.11.23
€3.64
29.11.24
29.11.24
122.78%
30.11.24
30.11.24